Expanding the structural footprint of xenoestrogens

Endocrine Disruptors

Volumn 2, Issue 1, 2014, Pages

  Baker, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

27 hydroxy cholesterol; 5 androstanediol; Endocrine disruptors; Xenoestrogens; 5 androstenediol

Indexed keywords

26 HYDROXYCHOLESTEROL; ALDOSTERONE; ANDROSTANEDIOL; ANDROSTENEDIOL; CYCLOHEXANE DERIVATIVE; ENDOCRINE DISRUPTOR; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYDROCORTISONE; HYDROXYL GROUP; METHYL GROUP; PLANT MEDICINAL PRODUCT; PROGESTERONE; STEROID; TESTOSTERONE; UNCLASSIFIED DRUG; XENOESTROGEN;

ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; ESTROGEN ACTIVITY; HUMAN; HYDROGEN BOND; NONHUMAN; TRANSCRIPTION INITIATION;

EID: 84940066269     PISSN: None     EISSN: 23273747     Source Type: Journal    
DOI: 10.4161/23273739.2014.967138     Document Type: Article

References (67)

1. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138:863-70; PMID:9048584
2. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87:905-31; PMID:17615392; http://dx.doi.org/10.1152/physrev. 00026.2006
3. Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 2011; 31:364-442; PMID:19967775; http://dx.doi. org/10.1002/med.20186
4. Leitman DC, Paruthiyil S, Vivar OI, Saunier EF, Herber CB, Cohen I, Tagliaferri M, Speed TP. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol 2010; 10:629-36; PMID:20951642; http://dx.doi. org/10.1016/j.coph.2010.09.009
5. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008; 73:233-44; PMID:18093629; http://dx.doi.org/10.1016/j.steroids.2007.10.013
6. Gao H, Dahlman-Wright K. The gene regulatory networks controlled by estrogens. Mol Cell Endocrinol 2011; 334:83-90; PMID:20837099; http://dx.doi.org/10.1016/j.mce.2010.09.002
7. Sugiyama N, Barros RP, Warner M, Gustafsson JA. ERbeta: recent understanding of estrogen signaling. Trends Endocrinol Metab 2010; 21:545-52; PMID:20646931; http://dx.doi.org/10.1016/j.tem. 2010.05.001
8. Zuloaga KL, O'Connor DT, Handa RJ, Gonzales RJ. Estrogen receptor beta dependent attenuation of cytokine- induced cyclooxygenase-2 by androgens in human brain vascular smooth muscle cells and rat mesenteric arteries. Steroids 2012; 77:835-44; PMID:22542504; http://dx.doi.org/10.1016/j.steroids.2012.04.013
9. Barros RP, Gustafsson JA. Estrogen receptors and the metabolic network. Cell Metab 2011; 14:289-99;PMID:21907136; http://dx.doi.org/10.1016/j.cmet. 2011.08.005
10. Katzenellenbogen JA. The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands. J Med Chem 2011; 54:5271-82; PMID:21707083; http://dx. doi.org/10.1021/jm200801h
11. Korach KS, Sarver P, Chae K, McLachlan JA, McKinney JD. Estrogen receptor-binding activity of polychlorinated hydroxybiphenyls: conformationally restricted structural probes. Mol Pharmacol 1988; 33:120-6; PMID:3122017
12. Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993; 101:378-84; PMID:8080506; http://dx.doi.org/10.1289/ehp.93101378
13. Carlson DB, Williams DE. 4-hydroxy-20,40,60-trichlorobiphenyl and 4-hydroxy-20,30,40,50-tetrachlorobiphenyl are estrogenic in rainbow trout. Environ Toxicol Chem 2001; 20:351-8; PMID:11351435; http://dx.doi.org/10.1002/etc.5620200216
14. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006; 116:561-70; PMID:16511588; http://dx.doi.org/10.1172/JCI27987
15. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30:293-342; PMID:19502515; http://dx.doi.org/10.1210/er.2009-0002
16. Oehlmann J, Schulte-Oehlmann U, Kloas W, Jagnytsch O, Lutz I, Kusk KO, Wollenberger L, Santos EM, Paull GC, Van Look KJ, et al. A critical analysis of the biological impacts of plasticizers on wildlife. Philos Trans R Soc Lond B Biol Sci 2009; 364:2047-62; PMID:19528055; http://dx.doi.org/10.1098/rstb.2008.0242
17. Manikkam M, Guerrero-Bosagna C, Tracey R, Haque MM, Skinner MK. Transgenerational actions of environmental compounds on reproductive disease and identification of epigenetic biomarkers of ancestral exposures. PLoS One 2012; 7:e31901.
18. Li Y, Luh CJ, Burns KA, Arao Y, Jiang Z, Teng CT, Tice RR, Korach KS. Endocrine-Disrupting Chemicals (EDCs): In Vitro Mechanism of Estrogenic Activation and Differential Effects on ER Target Genes. Environ Health Perspect 2013; 121:459-66, 66e1-6.
19. Swedenborg E, Pongratz I, Gustafsson JA. Endocrine disruptors targeting ERbeta function. Int J Androl 2010; 33:288-97; PMID:20050941; http://dx.doi.org/10.1111/j.1365-2605.2009.01025.x
20. Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol 2014; 139:225-36; PMID:23270754; http://dx.doi.org/10.1016/j.jsbmb.2012.12.004
21. Chandsawangbhuwana C, Baker ME. 3D models of human ERalpha and ERbeta complexed with coumestrol. Steroids 2014; 80:37-43; PMID:24315835; http://dx.doi.org/10.1016/j.steroids.2013.11.019
22. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753-8; PMID:9338790; http://dx.doi.org/10.1038/39645
23. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999; 18:4608-18; PMID:10469641; http://dx.doi.org/10.1093/emboj/18.17.4608
24. Manas ES, Unwalla RJ, Xu ZB, Malamas MS, Miller CP, Harris HA, Hsiao C, Akopian T, Hum WT, Malakian K, et al. Structure-based design of estrogen receptor- beta selective ligands. J Am Chem Soc 2004; 126:15106-19; PMID:15548008; http://dx.doi.org/10.1021/ja047633o
25. Mocklinghoff S, Rose R, Carraz M, Visser A, Ottmann C, Brunsveld L. Synthesis and crystal structure of a phosphorylated estrogen receptor ligand binding domain. Chembiochem 2010; 11:2251-4; PMID:20922740; http://dx.doi.org/10.1002/cbic.201000532
26. TanenbaumDM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A 1998; 95:5998-6003; PMID:9600906; http://dx.doi.org/10.1073/pnas.95.11.5998
27. Warnmark A, Treuter E, Gustafsson JA, Hubbard RE, Brzozowski AM, Pike AC. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J Biol Chem 2002; 277:21862-8; PMID:11937504; http://dx.doi.org/10.1074/jbc. M200764200
28. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139:4252-63; PMID:9751507
29. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95:927-37; PMID:9875847; http://dx.doi.org/10.1016/S0092-8674(00)81717-1
30. Manas ES, Xu ZB, Unwalla RJ, Somers WS. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Structure 2004; 12:2197-207; PMID:15576033; http://dx.doi.org/10.1016/j.str.2004.09.015
31. Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D. Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology 1993; 132:2279-86; PMID:8504731
32. le Maire A, Bourguet W, Balaguer P. A structural view of nuclear hormone receptor: endocrine disruptor interactions. Cell Mol Life Sci 2010; 67:1219-37; PMID:20063036; http://dx.doi.org/10.1007/s00018-009-0249-2
33. Baker ME. Insights from the structure of estrogen receptor into the evolution of estrogens: Implications for endocrine disruption. Biochem Pharmacol 2011; 82:1-8; PMID:21420388; http://dx.doi.org/10.1016/j. bcp.2011.03.008
34. Delfosse V, Grimaldi M, Pons JL, Boulahtouf A, le Maire A, Cavailles V, Labesse G, Bourguet W, Balaguer P. Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes. Proc Natl Acad Sci U S A 2012; 109:14930-5; PMID:22927406; http://dx.doi. org/10.1073/pnas.1203574109
35. Dodds EC, Lawson W. Synthetic oestrogenic agents without a phenanthrene nucleus. Nature 1936; 137:996; http://dx.doi.org/10.1038/137996a0
36. Huggins C, Jensen EV, Cleveland AS. Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat. J Exp Med 1954; 100:225-40; PMID:13192249; http://dx.doi.org/10.1084/jem.100.3.225
37. Adams J, GarciaM, Rochefort H. Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res 1981; 41:4720-6; PMID:6458355
38. Van Doorn LG, Berenschot-Roozendaal J, Poortman J, Thijssen JH, Schwarz F. Binding characteristics of 5-androstene-3 beta, 17 beta-diol and estradiol-17 beta to the cytoplasmic estrogen receptor of the immature rat uterus. J Steroid Biochem 1982; 16:661-71; PMID:7098481; http://dx.doi.org/10.1016/0022-4731 (82)90103-0
39. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci U S A 2002; 99:13589-94; PMID:12370428; http://dx.doi. org/10.1073/pnas.162477299
40. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW, Mangelsdorf DJ. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007; 13:1185-92; PMID:17873880; http://dx.doi.org/10.1038/nm1641
41. Gosselin D, Rivest S. Estrogen receptor transrepresses brain inflammation. Cell 2011; 145:495-7; PMID:21565607; http://dx.doi.org/10.1016/j.cell.2011.04.018
42. Baker ME. What are the physiological estrogens? Steroids 2013; 78:337-40; PMID:23313336; http://dx. doi.org/10.1016/j.steroids.2012.12.011
43. Garcia M, Rochefort H. Evidence and characterization of the binding of two 3H-labeled androgens to the estrogen receptor. Endocrinology 1979; 104:1797-804; PMID:571799; http://dx.doi.org/10.1210/endo-104-6-1797
44. Saijo K, Collier JG, Li AC, Katzenellenbogen JA, Glass CK. An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 2011; 145:584-95; PMID:21565615; http://dx. doi.org/10.1016/j.cell.2011.03.050
45. Muthusamy S, Andersson S, Kim HJ, Butler R, Waage L, Bergerheim U, Gustafsson JA. Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci U S A 2011; 108:20090-4; PMID:22114194; http://dx.doi.org/10.1073/pnas. 1117772108
46. Zuloaga KL, Swift SN, Gonzales RJ, Wu TJ, Handa RJ. The androgen metabolite, 5alpha-androstane-3beta,17-beta-diol, decreases cytokine-induced cyclooxygenase-2, vascular cell adhesion molecule-1 expression, and P-glycoprotein expression in male human brain microvascular endothelial cells. Endocrinology 2012; 153:5949-60; PMID:23117931; http://dx.doi.org/10.1210/en.2012-1316
47. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013; 342:1094-8; PMID:24288332; http://dx.doi. org/10.1126/science.1241908
48. Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 2013; 5:637-45; PMID:24210818; http://dx. doi.org/10.1016/j.celrep.2013.10.006
49. Baker ME, Uh KY, Chandsawangbhuwana C. 3D models of human ERalpha and ERbeta complexed with 5-androsten-3beta,17beta-diol. Steroids 2012; 77:1192-7; PMID:22921477; http://dx.doi.org/10.1016/j.steroids.2012.07.014
50. Nettles KW, Bruning JB, Gil G, O'Neill EE, Nowak J, Guo Y, Kim Y, DeSombre ER, Dilis R, Hanson RN, et al. Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep 2007; 8:563-8; PMID:17468738; http://dx.doi.org/10.1038/sj.embor. 7400963
51. Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. J Comput Chem 2007; 28:1145-52; PMID:17274016; http://dx.doi.org/10.1002/jcc.20634
52. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31:455-61; PMID:19499576
53. Forli S, Olson AJ. A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking. J Med Chem 2012; 55:623-38; PMID:22148468; http://dx.doi.org/10.1021/jm2005145
54. Baker ME. Recent insights into the origins of adrenal and sex steroid receptors. J Mol Endocrinol 2002; 28:149-52; PMID:12063181; http://dx.doi.org/10. 1677/jme.0.0280149
55. Baker ME. Origin and diversification of steroids: coevolution of enzymes and nuclear receptors. Mol Cell Endocrinol 2011; 334:14-20; PMID:20654689; http://dx.doi.org/10.1016/j.mce.2010.07.013
56. Finnerty JR. Evolutionary developmental biology. Head start. Nature 2000; 408:778-9, 81; PMID:11130701; http://dx.doi.org/10.1038/35048648
57. Lacalli TC. Basic features of the ancestral chordate brain: a protochordate perspective. Brain Res Bull 2008; 75:319-23; PMID:18331892; http://dx.doi.org/10.1016/j.brainresbull.2007.10.038
58. Green SA, Bronner ME. Gene duplications and the early evolution of neural crest development. Semin Cell Dev Biol 2013; 24:95-100; PMID:23287633; http://dx.doi.org/10.1016/j.semcdb.2012.12. 006
59. Medeiros DM. The evolution of the neural crest: new perspectives from lamprey and invertebrate neural crest-like cells. Wiley Interdisciplinary Rev Dev Biol 2013; 2:1-15; PMID:23799627; http://dx.doi.org/10.1002/wdev.85
60. Auchus RJ, Rainey WE. Adrenarche - physiology, biochemistry and human disease. Clin Endocrinol (Oxf) 2004; 60:288-96; PMID:15008992
61. Remer T, Boye KR, Hartmann MF, Wudy SA. Urinary markers of adrenarche: reference values in healthy subjects, aged 3-18 years. J Clin Endocrinol Metab 2005; 90:2015-21; PMID:15671100; http://dx.doi.org/10.1210/jc.2004-1571
62. Remer T, Manz F, HartmannMF, Schoenau E, Wudy SA. Prepubertal healthy children's urinary androstenediol predicts diaphyseal bone strength in late puberty. J Clin Endocrinol Metab 2009; 94:575-8; PMID:19001521; http://dx. doi.org/10.1210/jc.2008-1375
63. Thankamony A, Ong KK, Ahmed ML, Ness AR, Holly JM, Dunger DB. Higher levels of IGF-I and adrenal androgens at age 8 years are associated with earlier age at menarche in girls. J Clin Endocrinol Metab 2012; 97:E786-90; PMID:22419724; http://dx.doi.org/10.1210/jc.2011-3261
64. Finch CE. The menopause and aging, a comparative perspective. J Steroid Biochem Mol Biol 2014; 142C:132-41; http://dx.doi.org/10.1016/j.jsbmb.2013.03.010
65. Lasley BL, Chen J, Stanczyk FZ, El Khoudary SR, Gee NA, Crawford S, McConnell DS. Androstenediol complements estrogenic bioactivity during the menopausal transition. Menopause 2012; 19:650-7; PMID:22415563; http://dx.doi.org/10.1097/gme.0b013e31823df577
66. Lasley BL, Crawford S, McConnell DS. Adrenal androgens and the menopausal transition. Obstet Gynecol Clin North Am 2011; 38:467-75; PMID:21961714; http://dx.doi.org/10.1016/j.ogc.2011.06.001
67. Dobzhansky T. Nothing in Biology Makes Sense except in Light of Evolution. Am Biol Teach 1973; 35:125-9; http://dx.doi.org/10.2307/4444260